[The clinico-immunological efficacy of paspat and prodigiozan in the combined treatment of infectious-allergic bronchial asthma].
64 patients with infectious-allergic bronchial asthma (IABA) were examined. 20 of them were co-administered paspat, 24 patients additionally received prodigiosan, 20 patients constituted control group and were given conventional treatment. Patients of all the groups were comparable in age, state of immunological reactivity of the body and severity of the disease. Immunomodulatory effect of the drugs, mainly of paspat, not only resulted in normalization of functional properties of granulocytes but also promoted liquidation of quantitative and functional IABA-conditioned immunodeficiency on the part of T- and B-lymphocytes, thus increasing effectiveness of the treatment in the whole.